

1 **Full Title: Correlation Between Blood and CSF Compartment Cytokines and Chemokines**  
2 **in Subjects with Cryptococcal Meningitis.**

3

4 Elizabeth C Okafor<sup>1</sup>, Katherine H Hullsiek<sup>2</sup>, Darlisha A Williams<sup>1,3</sup>, James E Scriven<sup>4</sup>, Joshua  
5 Rhein<sup>1,3</sup>, Henry W Nabeta<sup>3</sup>, Abdu K Musubire<sup>3</sup>, Radha Rajasingham<sup>1</sup>, Conrad Muzoora<sup>5</sup>,  
6 Charlotte Schutz<sup>4</sup>, Graeme Meintjes<sup>4</sup>, David B Meya<sup>1,3</sup>, David R Boulware<sup>1</sup>.

7

8 <sup>1</sup> Department of Medicine, University of Minnesota, 55455 Minneapolis, MN, USA.

9 <sup>2</sup> School of Public Health, University of Minnesota, 55455 Minneapolis, MN, USA

10 <sup>3</sup>Infectious Diseases Institute, Makerere University, P.O. Box 22418 Kampala, Uganda.

11 <sup>4</sup> Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease  
12 and Molecular Medicine, and Department of Medicine, Observatory 7925 University of Cape  
13 Town, South Africa.

14 <sup>5</sup>Department of Medicine, Mbarara University of Science and Technology, P.O. Box 1410  
15 Mbarara, Uganda.

16

17 **Corresponding Author:**

18 Elizabeth Okafor

19 Microbiology Research Facility 4-103

20 689 23 rd Ave SE

21 Minneapolis, MN 5455 USA

22 **Email:** [okafo039@umn.edu](mailto:okafo039@umn.edu)

23

24 **Alternate:** David Boulware [boulw001@umn.edu](mailto:boulw001@umn.edu)

25

26

27 **ABSTRACT**

28 *Background:* Though peripheral blood is a crucial sample to study immunology, it is unclear  
29 whether the immune environment in the peripheral vasculature correlates with that at the end-  
30 organ site of infection. Utilizing cryptococcal meningitis as a model, we investigated the  
31 correlation between serum and cerebrospinal fluid biomarkers over time. *Methods:* We analyzed  
32 the cerebrospinal fluid and serum of 160 subjects presenting with first episode cryptococcal  
33 meningitis for soluble cytokines and chemokines measured by Luminex assay. Specimens were  
34 collected at meningitis diagnosis, 1-week, and 2-weeks post cryptococcal diagnosis. We  
35 compared paired samples by Spearman correlation and the p-value was set at <0.01. *Results:*  
36 Of the 21 analytes tested at baseline, there was no correlation detected between nearly all  
37 analytes. A weak negative correlation was found between serum and cerebrospinal fluid levels  
38 of interferon-gamma (Rho= -0.214, p= .007) and interleukin- 4 (Rho= -0.232, p=. 003). There  
39 was no correlation at 1-week post cryptococcal diagnosis. However, at 2-weeks post diagnosis,  
40 there was a weak positive correlation between levels of granulocyte-macrophage colony-  
41 stimulating factor (Rho= 0.25, p= .007) between serum and cerebrospinal fluid. No cytokine or  
42 chemokine showed consistent correlation overtime. *Conclusion:* Based on our analysis of 21  
43 biomarkers, serum and cerebrospinal fluid immune responses do not correlate. There appears  
44 to be a distinct immune environment in terms of soluble biomarkers in the vasculature versus  
45 end-organ site of infection. While this is a model of HIV-related cryptococcal meningitis, we  
46 postulate that assuming the blood compartment is representative of the immune function at the  
47 end-organ site of infection may not be appropriate.

48

49

50 **Word Count:** Abstract - 256 words; Manuscript – 1738

51

52 **INTRODUCTION:**

53

54 Immunologic investigations are critical to understanding the pathogenesis of infectious  
55 disease. Often human or animal subjects have their blood drawn to assess cell phenotype,  
56 function, or soluble cytokines or chemokines in order to characterize the immune response to  
57 infection. Blood is a convenient and available compartment to analyze. However, it is unclear if  
58 analysis of cells trafficking in the peripheral vasculature reflects the actual immune response at  
59 the end organ site compartment (e.g. CSF in meningitis, lung in pneumonia). This is important  
60 because the end organ site of infection is often the primary site from which initial or disease-  
61 specific signs and symptoms manifest. Of even more concern is the possibility of unknowingly  
62 overestimating or underestimating the immune response based on analysis of immune cells in  
63 the vasculature.

64

65 Analysis of site-specific immune responses in humans is difficult but not impossible.  
66 Cryptococcal meningitis is one model which allows investigation of the compartment-specific  
67 immune responses. In cryptococcal meningitis, frequent therapeutic lumbar punctures to control  
68 intracranial pressure provide a large volume of CSF over the course of treatment. Analysis of  
69 CSF provides information about the immune responses in the central nervous system (CNS).  
70 Yet, cryptococcal meningitis is not solely a localized CNS infection, but a systemic infection  
71 whereby inhaled cryptococcal spores germinate in the lung and yeast cells disseminate via the  
72 blood throughout the body [1, 2]. Peripheral blood mononuclear cells, serum, and plasma  
73 provide information about immune responses in the peripheral vascular compartment.

74

75 In cryptococcosis, but more broadly in infectious disease, the correlation between the  
76 immune response in the peripheral vasculature versus immune response in the end-organ  
77 compartment is poorly characterized. The objective of the present analysis is to determine the

78 correlation between 21 peripheral blood and CSF cytokines and chemokines in a cohort of  
79 subjects with first episode cryptococcosis. In addition, we report the correlation results over time  
80 using three distinct timepoints during the course of cryptococcosis treatment. The results from  
81 this analysis identifies similarities and differences in the immune responses, particularly soluble  
82 cytokines and chemokines, in tissue compartments by using cryptococcal meningitis as a  
83 representative model.

84

## 85 **MATERIALS AND METHODS**

86

87 Subjects with first episode of cryptococcal meningitis were originally enrolled in the  
88 Cryptococcal Optimal ART Timing (COAT) trial from November 2010 to April 2012 to determine  
89 the optimal time to initiate antiretrovirals after cryptococcal meningitis [3]. The COAT trial was  
90 conducted at: Mulago Hospital, Kampala, Uganda; Mbarara University of Science and  
91 Technology, Mbarara, Uganda; and the former G.F. Jooste Hospital in Cape Town, South  
92 Africa. All subjects completed written informed consent and the institutional review board from  
93 each organization approved the study protocol. Details regarding this study trial have been  
94 previously described (Clinicaltrials.gov Identifier No: NCT01075152) [3].

95

96 We collected peripheral blood and CSF samples at cryptococcal meningitis diagnosis,  
97 trial randomization at 1-week, and 2-weeks post cryptococcal meningitis diagnosis. The  
98 samples were processed and stored at -80 and then shipped to the University of Minnesota for  
99 analysis. Samples did not undergo any prior freeze thaws. Serum and CSF were analyzed in a  
100 T cell and macrophage targeted multiplex panel for 19 cytokines and chemokines using a  
101 Luminex multiplex cytokine panel (Bio-Rad, Hercules, CA) [4], following the manufacturer's  
102 instructions being run at 1:2 dilution taking the average of two replicates. We also measured

103 CD14 and CD163 by ELISA (R&D Systems, Minneapolis, MN). We have previously reported the  
104 longitudinal CSF changes by early vs late ART treatment [4].

105

106 To assess the correlation between intra-subject matched serum and CSF cytokines we  
107 log transformed the raw readout and subsequently used a non-parametric Spearman correlation  
108 test. Data at each time point represents all subjects included in the previous study irrespective  
109 of trial arm randomization. Changes in cohort size represents fluctuations in specimen  
110 availability, most often due to subjects who declined therapeutic lumbar punctures or subjects  
111 who unfortunately died. Significance was set at a p-value of 0.01 to adjust for multiple  
112 comparisons in a post-hoc exploratory analysis.

113

## 114 **RESULTS**

115

116 Of 177 ART-naïve subjects with first episode of cryptococcal meningitis enrolled into the  
117 COAT trial, matching CSF and serum existed for 160 subjects at baseline, 105 subjects at 1-  
118 week, and 115 subjects at 2-weeks. Missing specimens were most often due to lack of CSF  
119 collection on the same day as serum collection as subjects could refuse therapeutic lumbar  
120 punctures. Clinical and demographic data comparing COAT trial arms early versus late ART  
121 initiation have been previously described [4]. Of the 160 subjects included in this analysis, 79  
122 subjects (49%) were female. The median age was 35 (interquartile range (IQR) 28.5 to 40)  
123 years with a median CD4 count of 25 (IQR 10 to 74) cells/ $\mu$ L determined at 1-week post  
124 diagnosis.

125

126 We assessed whether there was a correlation between immune biomarkers in CSF  
127 versus serum for 21 analytes irrespective of study arm randomization. At time of diagnosis,  
128 none of the 21 immune biomarkers had a positive correlation by Spearman's non-parametric

129 test (**Table 1**). Two analytes had statistically significant but weak negative correlations; the type  
130 1 T-helper cell (Th<sub>1</sub>) cytokine interferon-gamma (IFN- $\gamma$ , Rho= -0.214, p=.007) and the type 2 T-  
131 helper cell cytokine (Th<sub>2</sub>) interleukin-4 (IL-4, Rho= -0.232, p=.003). While statistically significant,  
132 the correlations were relatively weak and inverse for both IFN- $\gamma$  and IL-4 (**Figure 1**), meaning as  
133 blood levels increased, CSF levels decreased.

134

135 Of the 19 biomarkers analyzed among 105 paired samples at 1-week post cryptococcal  
136 meningitis diagnosis, no cytokines or chemokines were statistically correlated. Of the 21  
137 biomarkers analyzed at 2-weeks post diagnosis among 115 paired samples, a weak positive  
138 correlation existed between serum and CSF levels of granulocyte-macrophage colony-  
139 stimulating factor (GM-CSF, Rho=0.25, p=.007). Across the three time points as subjects  
140 continued standard antifungal therapy, GM-CSF was the only cytokine with a significant  
141 correlation between blood and CSF (Rho= 0.147, p=0.003) (**Table 2**). Additionally, analysis of  
142 rate of change over time, through slope calculation across all three time points, demonstrated  
143 no significant positive or negative correlation between blood and CSF (**Table 2**).

144

## 145 **DISCUSSION**

146

147 We hypothesized that immune biomarkers would have a general positive correlation  
148 between serum and CSF. Surprisingly, we found no consistent correlation between soluble  
149 immune biomarkers in the peripheral vasculature versus at the site of infection in the CSF. The  
150 cytokine environment was strikingly different, even though cryptococcosis is a disseminated  
151 infection throughout the vasculature, lungs, and CNS [2, 5, 6]. Additionally, no single analyte  
152 had a significant correlation pattern over the course of the first two weeks of standard antifungal  
153 therapy. The results from this focused analysis provide evidence that peripheral blood analytes

154 are not necessarily similar to CSF analytes. This builds upon our previous findings which  
155 demonstrated that lymphocyte populations and activation levels in CSF are distinct from  
156 peripheral blood [7].

157

158 There is a large body of published literature comparing human peripheral blood and CSF  
159 cytokines and chemokines across various infectious etiologies of meningitis. Comparatively,  
160 little literature has been published regarding the correlation within the same individuals' between  
161 human tissue compartments and peripheral blood analytes in infectious etiologies of meningitis  
162 [8] or other conditions. Additionally, prior to this study, there was no literature characterizing  
163 CSF and blood analyte correlations over time in subjects with cryptococcal meningitis.

164

165 Employing cryptococcal meningitis as a model of compartmentalization, we raise a  
166 fundamental question of whether the immunology observed in peripheral blood represents what  
167 occurs at the end-organ site of infection. This is particularly important as the infectious disease  
168 field continues to consider the potential benefits and risks of immunomodulating agent adjuvant  
169 therapy, such as administration of proinflammatory cytokines and/or monoclonal antibodies to  
170 inhibit anti-inflammatory cytokines or exhaustion receptor engagement. Therefore, it is crucial to  
171 truly understand the immune environment at the end-organ site of infection.

172

173 The effector immune response at the site of infection appears to be very different from  
174 that of cells trafficking in blood. Previous studies on cryptococcal meningitis immune  
175 reconstitution inflammatory syndrome documented differential expression of leukocyte  
176 phenotype when comparing peripheral blood to the CSF [7]. We doubt these findings are unique  
177 to cryptococcosis, for example as demonstrated by differential gene expression when  
178 comparing pericardial fluid to peripheral blood in subjects with pericardial tuberculosis [9]. There  
179 is also the potential impact of tissue niche on leukocyte activation and cytokine environment.

180 Research on compartmentalization in infection is limited and thus characterizing the immune  
181 response in peripheral blood vs end-organ compartments should be rigorously assessed in  
182 other localized infections.

183

184 Our study is restricted to immunocompromised persons with cryptococcosis, thus  
185 whether the lack of correlation between tissue-specific and peripheral vasculature compartment  
186 immune responses is universal, requires future study. Additionally, the repertoire of cytokines  
187 and chemokines tested in this analysis include those generated by several T cells subsets,  
188 particularly Th1 and Th2 effector T cells, that have been implicated in favorable and detrimental  
189 outcomes respectively in mice with cryptococcal meningitis [10, 11]. The panel also includes  
190 several molecules important for macrophage activation and polarization [12] as it has been  
191 demonstrated that M1 macrophage polarization enhances *cryptococcus* clearance [13]. Though  
192 larger cytokine and chemokine panels are available, this targeted panel includes important  
193 analytes that have been consistently studied in cryptococcal meningitis. Therefore, this panel  
194 may require modification when analyzing tissue-specific immune responses in other disease  
195 states.

196

197 It is plausible that participants' study arm randomization to early or late ART, based on  
198 parent clinical trial, could have affected cytokine responses. However, all participants in the  
199 parent clinical trial irrespective of study arm randomization, were included in this analysis if CSF  
200 and serum compartment matched samples from the same individual were available for analysis.  
201 Therefore, it is unlikely that study arm randomization could impact our intra-person correlation  
202 analysis. Though 160 subjects were included in the baseline analysis, our data are limited by  
203 the absence of 35% and 30% of study participants' specimens at 1 and 2 weeks, respectively.  
204 However, we postulate that more specimens would not have changed the generally poor  
205 strength of the correlations. The strength of correlations for all analytes was generally weak with



206 Rho correlation coefficient ranging from -0.23 to +0.25. Thousands of specimens may have  
207 been able to generate a statistically significant p-value, but the correlations were weak.  
208 Additionally, a more stringent and formal p-value calculation, (for example Bonferroni correction  
209 or Benjamini-Hochberg procedure) would not have changed the overall weak correlation.

210

## 211 **CONCLUSION**

212

213 In conclusion, we demonstrate that cytokines and chemokines released upon leukocyte  
214 activation do not correlate between serum and CSF in cryptococcal meningitis. This  
215 demonstrates that, though readily available, utilizing peripheral blood as an approximation for  
216 the immune status in tissue compartments, such as the CNS, is potentially unreliable.

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232 **Data Availability:**

233 The data used to support the findings in this study are available upon request sent to the  
234 corresponding author.

235

236 **Potential Conflict of Interest:**

237 The authors declare that there is no conflict of interest regarding the publication of this paper.

238

239 **Funding Statement:**

240 This research was supported by the National Institute of Allergy and Infectious Diseases  
241 (R01NS086312, U01AI125003, T32AI055433, K23AI138851), National Institute of Neurologic  
242 Disorders and Stroke (NINDS) and Fogarty International Center (R01NS086312,  
243 K01TW010268, K43TW010718).

244

245 **Acknowledgements:**

246 We would like to thank the medical officers, nurses, and laboratory staff who were a part of the  
247 COAT Study Team. Additionally, we express our deepest gratitude to all study participants,  
248 healthcare professionals, and laboratory staff at all study sites.

249

250 **Disclaimer:** The findings from this project have not been previously presented at any  
251 conferences and is not being considered for publication by another journal at this time.

252

253 **References**

254

- 255 1. Coelho C, Bocca AL, Casadevall A. The Intracellular Life of *Cryptococcus neoformans*.  
256 Annu Rev Pathol **2014**; 9: 219-38.
- 257 2. Denham ST, Brown JCS. Mechanisms of Pulmonary Escape and Dissemination by  
258 *Cryptococcus neoformans*. Journal of Fungi **2018**; 4(25).
- 259 3. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after  
260 diagnosis of cryptococcal meningitis. N Engl J Med **2014**; 370(26): 2487-98.
- 261 4. Scriven JE, Rhein J, Hullsiek KH, et al. Early ART after cryptococcal meningitis is  
262 associated with cerebrospinal fluid pleocytosis and macrophage activation in a multisite  
263 randomized trial. J Infect Dis **2015**; 212(5): 769-78.
- 264 5. Vanherp L, Ristani A, Poelmans J, et al. Sensitive bioluminescence imaging of fungal  
265 dissemination to the brain in mouse models of cryptococcosis. Dis Model Mech **2019**;  
266 12(6): dmm039123.
- 267 6. Nicola AM, Robertson EJ, Albuquerque P, Derengowski LdS, Casadevall A. Nonlytic  
268 Exocytosis of *Cryptococcus neoformans* from Macrophages Occurs In Vivo and Is  
269 Influenced by Phagosomal pH. mBio **2011**; 2(4): e00167-11.
- 270 7. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid  
271 from ugandans with cryptococcal meningitis and immune reconstitution inflammatory  
272 syndrome. J Infect Dis **2015**; 211(10): 1597-606.
- 273 8. Fassbender K, Schminke U, Ries S, et al. Endothelial-derived adhesion molecules in  
274 bacterial meningitis: association to cytokine release and intrathecal leukocyte-  
275 recruitment. J Neuroimmunol **1997**; 74(1-2): 130-4.
- 276 9. Matthews K, Deffur A, Ntsekhe M, et al. A Compartmentalized Profibrotic Immune  
277 Response Characterizes Pericardial Tuberculosis, Irrespective of HIV-1 Infection. Am J  
278 Respir Crit Care Med **2015**; 192(12): 1518-21.
- 279 10. Wiesner DL, Specht CA, Lee CK, et al. Chitin Recognition via Chitotriosidase Promotes  
280 Pathologic Type-2 Helper T Cells Responses to Cryptococcal Infection. PLoS Pathogens  
281 **2015**; 11(3): e1004701.
- 282 11. Müller U, Stenzel W, Köhler G, et al. IL-13 Induces Disease-Promoting type 2 Cytokines,  
283 Alternatively Activated Macrophages and Allergic Inflammation during Pulmonary  
284 Infection of Mice with *Cryptococcus neoformans*. J Immunol **2007**; 179: 5367-55377.
- 285 12. Chiller T, Farrokhsad K, Brummer E, Stevens DA. Effect of granulocyte colony-  
286 stimulating factor and granulocyte-macrophage colony-stimulating factor on  
287 polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages  
288 combined with voriconazole against *Cryptococcus neoformans*. Medical Mycology **2002**;  
289 40: 21-6.

290 13. Hardison SE, Ravi S, Wozniak KL, Young ML, Olszewski MA, Jr FLW. Pulmonary  
291 Infection with an Interferon-gamma Producing *Cryptococcus neoformans* Strain Results  
292 in Classical Macrophage Activation and Protection. Am J Pathol 2010, **2010**; 176(2):  
293 774–85.  
294

295

296

297 **Table 1: Correlation of Paired CSF and Serum Analytes at Baseline, 1-Week, and 2-Weeks**  
 298 **post Cryptococcal Meningitis Diagnosis.**

299

Biomarker	At CM diagnosis			1-week post diagnosis			2-weeks post CM diagnosis		
	N	Rho	P-value	N	Rho	P-value	N	Rho	P-value
<i>Innate Immune response</i>									
IL-6	160	0.021	0.79	105	-0.025	0.80	115	-0.228	0.01
IL-1 $\beta$	160	-0.042	0.60	105	-0.122	0.22	115	0.052	0.58
IL-8	160	-0.034	0.67	105	0.141	0.15	115	0.035	0.71
G-CSF	160	-0.003	0.97	105	0.1	0.31	115	0.087	0.36
GM-CSF	160	0.033	0.68	105	0.16	0.10	115	0.25	0.007*
MCP-1	160	0.133	0.09	105	0.216	0.03	115	-0.117	0.21
MIP-1 $\alpha$	75	0.01	0.93	5	0.4	0.51	93	-0.07	0.51
MIP-1 $\beta$	160	0.117	0.14	105	0.114	0.25	115	-0.057	0.55
CD14	87	0.078	0.47	n	N/A	N/A	83	0.187	0.09
CD163	87	-0.249	0.02	n	N/A	N/A	83	-0.099	0.38
<i>Adaptive Immune response</i>									
IFN- $\gamma$	160	-0.214	0.007*	105	0.089	0.37	115	0.198	0.03
TNF- $\alpha$	160	0.077	0.33	105	0.038	0.70	115	0.078	0.41
IL-12	160	0.09	0.26	105	-0.153	0.12	115	-0.005	0.96
IL-2	160	-0.025	0.76	105	-0.041	0.68	115	0.22	0.02
IL-7	160	0.038	0.64	105	0.11	0.26	115	-0.004	0.96
IL-10	160	0.021	0.80	105	0.045	0.65	115	-0.025	0.80
IL-5	160	-0.046	0.56	105	0.099	0.32	115	0.004	0.97
IL-4	160	-0.232	0.003*	105	0.107	0.28	115	-0.064	0.49
IL-13	160	0.056	0.48	105	-0.004	0.97	115	-0.057	0.54
IL-17	160	-0.008	0.92	105	0.128	0.19	115	0.012	0.90
<i>Hemostasis</i>									
VEGF	111	-0.049	0.61	62	0.062	0.63	115	-0.002	0.99

300

301 \*P value of less than 0.01.

302 Interleukin (IL), Interferon (IFN), Tumor- necrosis factor (TNF), Granulocyte-colony stimulating factor (G-CSF),


303 Granulocyte-macrophage colony stimulating factor (GM-CSF), Monocyte chemoattractant protein-1/CCL2 (MCP-1),

304 Macrophage inflammatory protein (MIP), and Vascular Endothelial Growth Factor (VEGF)

305

306 **Figure 1: Scatterplot of Interferon-Gamma (IFN- $\gamma$ ) and Interleukin-4 (IL-4) at Cryptococcal**  
307 **Meningitis in CSF Versus Serum.**

308



309

310 IFN- $\gamma$  is a Th<sub>1</sub> cytokine which is protective in cryptococcosis causing classical activation of macrophages to enhance  
311 killing of yeast. IL-4 is Th<sub>2</sub> cytokine which is not protective in mouse models of cryptococcosis. Both cytokines have a  
312 weak, inverse correlation between levels observed in serum versus CSF. Levels are in pg/mL.

313

314 **Table 2. Correlation of CSF and Serum Cytokines Pooled Across All Three Time Points**  
 315 **at Baseline, 1-Week, and 2-Weeks post Cryptococcal Meningitis Diagnosis.**

316

BIOMARKER	N	Rho	P-value	N	Rho	P-value
	<i>Combined Correlation</i>			<i>Rate of Change Over Time</i>		
<i>Innate Immune response</i>						
IL-6	403	-0.07	0.16	160	0.151	0.06
IL-1 $\beta$	403	0.029	0.57	160	0.070	0.38
IL-8	403	0.029	0.56	160	0.132	0.10
G-CSF	403	0.067	0.18	160	0.086	0.28
GM-CSF	403	0.147	0.003*	160	-0.030	0.70
MCP-1	403	0.073	0.15	160	0.111	0.16
MIP-1 $\alpha$	214	-0.127	0.06	118	0.061	0.51
MIP-1 $\beta$	403	0.10	0.05	160	-0.119	0.13
CD14	312	0.095	0.09	128	0.180	0.04
CD163	312	-0.051	0.37	128	-0.143	0.11
<i>Adaptive Immune response</i>						
IFN- $\gamma$	403	0.119	0.02	160	0.120	0.13
TNF- $\alpha$	403	0.102	0.04	160	0.096	0.23
IL-12	403	-0.021	0.67	160	-0.003	0.97
IL-2	403	0.089	0.08	160	-0.057	0.48
IL-7	403	0.036	0.47	160	-0.032	0.69
IL-10	403	-0.062	0.21	160	0.068	0.40
IL-5	403	0.041	0.41	160	0.059	0.46
IL-4	403	0.082	0.10	160	-0.063	0.43
IL-13	403	-0.093	0.06	160	0.194	0.014
IL-17	403	0.066	0.19	160	-0.082	0.30
				160		
<i>Hemostasis</i>						
VEGF	307	0.051	0.37	147	-0.059	0.48

317

318 \*P value of less than 0.01.

319 Interleukin (IL), Interferon (IFN), Tumor- necrosis factor (TNF), Granulocyte-colony stimulating factor (G-CSF),

320 Granulocyte-macrophage colony stimulating factor (GM-CSF), Monocyte chemoattractant protein-1/CCL2 (MCP-1),

321 Macrophage inflammatory protein (MIP), and Vascular Endothelial Growth Factor (VEGF)

322